Insider Selling: AtriCure (NASDAQ:ATRC) Director Sells $134,470.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,500 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director directly owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

AtriCure Price Performance

AtriCure stock opened at $41.39 on Monday. The business has a 50 day simple moving average of $32.25 and a 200 day simple moving average of $31.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The company has a market capitalization of $2.11 billion, a PE ratio of 197.10 and a beta of 1.20. AtriCure, Inc. has a one year low of $25.36 and a one year high of $43.18.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in AtriCure during the 2nd quarter worth $125,198,000. Deutsche Bank AG acquired a new stake in shares of AtriCure in the 2nd quarter valued at $1,670,000. Rice Hall James & Associates LLC bought a new stake in shares of AtriCure during the second quarter worth $3,755,000. Global Retirement Partners LLC bought a new stake in shares of AtriCure during the second quarter worth $52,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of AtriCure during the second quarter valued at $3,953,000. Institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group increased their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.